FYI: This is part 2 of an update on the latest fibromyalgia and Lyme disease research studies found on ClinicalTrials.gov.
As promised, here is part 2 of the most recent fibromyalgia and Lyme disease studies from ClinicalTrials.gov. In this update, we have fibromyalgia studies looking at if genetics plays a role in developing central sensitization; how the pandemic has impacted fear and anxiety levels among fibro patients; using the antibiotic minocycline as a fibromyalgia treatment and many other treatment-related research projects.
For my Lyme readers, there are studies for a new vaccine as well as a biomarker study for those who continue to have symptoms after antibiotic treatment.
As usual, there are WAY more fibro studies than Lyme studies. I’m still hoping the pace will increase once the federal government divvies up all those Lyme research dollars I keep reading about.
Are you excited or hopeful about any of these studies? Or do you feel like it’s just same old/same old? Share your thoughts in the comments section!
During this study out of University Hospital of Clermont-Ferrand in France, researchers will “characterize the predispositions of central sensitization and genetics in [around 300] patients with fibromyalgia compared to a control group matched in age, sex and menopausal status.”
(Read more: Is fibromyalgia hereditary?)
The aim of this study by researcher Susanne Becker from Balgrist University Hospital (Switzerland) “is to investigate the psychobiological mechanisms underlying the negative hedonic shift in chronic pain with a focus on the causal role of neuroinflammation (substudy 1) and the role of dopamine (substudy 2) in functional connectivity of fronto-striatal brain networks and their relation to heightened emotional-motivational pain processing.”
Low-dose naltrexone, a dopamine agonist (bromocriptine) or a dopamine antagonist (amisulpride) will be administered to 100 fibromyalgia patients.
Diskapi Yildirim Beyazit Education and Research Hospital researchers in Turkey will “analyze the effect of COVID-19 fear and anxiety on the daily life, sleep quality and depression-anxiety levels of fibromyalgia patients.”
Researchers from Philipps University Marburg Medical Center in Germany will study “the influence of positive affect and optimism on selective learning” among fibromyalgia patients.
During this small study, researcher Michael Gabriel Hillegass from the Medical University of South Carolina will evaluate if adding the antibiotic minocycline and the supplement N-acetylcysteine (i.e. NAC) to standard treatment will improve fibromyalgia pain levels.
Note: I think it’s interesting this researcher is exploring if antibiotics improve fibromyalgia symptoms. Over the years, I’ve had multiple doctors tell me around 30% or more of their fibromyalgia patients actually have undiagnosed chronic Lyme disease. Guess what’s used to treat chronic Lyme? Antibiotics like minocycline!
About 60 fibromyalgia patients will participate in a study at Bezmialem Vakif University in Turkey to “evaluate whether spinal manipulation, which is a potential treatment method for musculoskeletal pain, has an additional contribution in patients with fibromyalgia receiving standard pharmacological treatment.”
Riphah International University researchers in Pakistan will “compare the effects of Muscle Energy Techniques with breathing exercises for improving functional outcomes in patients with fibromyalgia.”
This Stanford University study will compare pain rehabilitation virtual reality vs. standard physiotherapy rehabilitation among adolescents with chronic musculoskeletal pain conditions like fibromyalgia.
Spanish researchers from the University of Seville are attempting to find out if “transcranial static magnetic field stimulation (tSMS) reduces the perception of pain in patients with fibromyalgia and its effect on health-related quality of life. In addition, it will seek to limit the parameters necessary to achieve efficiency with the technique,” reads ClinicalTrials.gov.
University of Michigan researchers will “evaluate the impact of explosive synchronization (ES) and its treatment with non-invasive brain stimulation in fibromyalgia. The study design has three components; however, only two aims are enrolling participants. The first part (aim 1) is a cross-sectional assessment of brain network explosive synchronization activity, connectivity and response to pain in healthy controls and age and sex-matched fibromyalgia patients. The third part (aim 3) is a longitudinal assessment of fibromyalgia patients undergoing one week of sham [treatment] followed by high-definition transcranial direct current stimulation (HD-tDCS) of the motor cortex or one week of ES HD-tDCS of a brain region identified from computer modelling (aim 2).”
More than 60 fibromyalgia patients will participate in a Brazilian study “to map the impact of anodic transcranial direct current stimulation (tDCS) for prolonged home use applied to the primary motor cortex and the left dorsolateral prefrontal córtex compared to the respective treatments simulated in fibromyalgia.”
This study sponsored by the Practitioners Alliance Network will determine if a supplement combining D-ribose, ashwagandha, rhodiola, schisandra, licorice and green tea extract improves pain, sleep, fatigue and cognition among fibromyalgia and chronic fatigue syndrome patients.
This Practitioners Alliance Network sponsored study will determine if HRG 80 red ginseng improves functionality and symptoms among 70 fibromyalgia and chronic fatigue syndrome patients.
Spanish researchers from the Hospital Universitari Vall d’Hebron Research Institute will compare patients who undergo treatment-as-usual plus a virtual FIBROWALK program to patients who only had treatment as usual.
This study involving researchers from the Hospital Universitari Vall d’Hebron Research Institute in Spain will compare the “usefulness of a new educational tool developed by Pain Revolution, a compendium of nine fact sheets along with a related quiz” in fibromyalgia patients versus those who didn’t receive the educational materials.
During this small Brazilian study, Federal University of Pelotas researchers will “verify the effects of a telehealth stretching exercise program on pain, depression, sleep parameters and functionality of women with fibromyalgia during the COVID-19 pandemic,” according to ClinicalTrials.gov.
Universidad Miguel Hernandez de Elche researchers in Spain seek to “establish the effectiveness of implementation intentions to manage the preference for avoiding pain and fatigue and stop walking exercise versus to maintain the approximate behavior (walking), taking into account high and low pain catastrophizing conditions.”
This study will track patient reported outcome measures (PROMs) for patients with bodily distress syndrome seeking treatment from Helsinki University’s Clinic for Functional Disorders in Finland.
(Read more: What is bodily distress syndrome?)
Researchers from Sohag University in Egypt will study how fibromyalgia affects disease activity in those with the comorbidities of rheumatoid arthritis or psoriatic arthritis, and its relation to vitamin D levels.
Lyme disease studies
FlightPath Biosciences, Inc. will compare biomarkers contained in blood and stool samples collected from people previously treated for Lyme disease versus health volunteers.
Around 600 healthy volunteers will test out three different schedules for administering a potential vaccine for Lyme disease.
This National Centre for ElectroMagnetic Therapies study in the United Kingdom will determine if PEMF therapy is effective for relieving or reducing lingering Lyme disease symptoms following antibiotic treatment.